Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
© 2019 The International Biometric Society..
In this paper, we propose a Bayesian design framework for a biosimilars clinical program that entails conducting concurrent trials in multiple therapeutic indications to establish equivalent efficacy for a proposed biologic compared to a reference biologic in each indication to support approval of the proposed biologic as a biosimilar. Our method facilitates information borrowing across indications through the use of a multivariate normal correlated parameter prior (CPP), which is constructed from easily interpretable hyperparameters that represent direct statements about the equivalence hypotheses to be tested. The CPP accommodates different endpoints and data types across indications (eg, binary and continuous) and can, therefore, be used in a wide context of models without having to modify the data (eg, rescaling) to provide reasonable information-borrowing properties. We illustrate how one can evaluate the design using Bayesian versions of the type I error rate and power with the objective of determining the sample size required for each indication such that the design has high power to demonstrate equivalent efficacy in each indication, reasonably high power to demonstrate equivalent efficacy simultaneously in all indications (ie, globally), and reasonable type I error control from a Bayesian perspective. We illustrate the method with several examples, including designing biosimilars trials for follicular lymphoma and rheumatoid arthritis using binary and continuous endpoints, respectively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Biometrics - 76(2020), 2 vom: 21. Juni, Seite 630-642 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Psioda, Matthew A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bayesian clinical trial design |
|---|
| Anmerkungen: |
Date Completed 26.08.2021 Date Revised 26.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/biom.13163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302376097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302376097 | ||
| 003 | DE-627 | ||
| 005 | 20231225110605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/biom.13163 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM302376097 | ||
| 035 | |a (NLM)31631321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Psioda, Matthew A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bayesian design of biosimilars clinical programs involving multiple therapeutic indications |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2021 | ||
| 500 | |a Date Revised 26.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The International Biometric Society. | ||
| 520 | |a In this paper, we propose a Bayesian design framework for a biosimilars clinical program that entails conducting concurrent trials in multiple therapeutic indications to establish equivalent efficacy for a proposed biologic compared to a reference biologic in each indication to support approval of the proposed biologic as a biosimilar. Our method facilitates information borrowing across indications through the use of a multivariate normal correlated parameter prior (CPP), which is constructed from easily interpretable hyperparameters that represent direct statements about the equivalence hypotheses to be tested. The CPP accommodates different endpoints and data types across indications (eg, binary and continuous) and can, therefore, be used in a wide context of models without having to modify the data (eg, rescaling) to provide reasonable information-borrowing properties. We illustrate how one can evaluate the design using Bayesian versions of the type I error rate and power with the objective of determining the sample size required for each indication such that the design has high power to demonstrate equivalent efficacy in each indication, reasonably high power to demonstrate equivalent efficacy simultaneously in all indications (ie, globally), and reasonable type I error control from a Bayesian perspective. We illustrate the method with several examples, including designing biosimilars trials for follicular lymphoma and rheumatoid arthritis using binary and continuous endpoints, respectively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Bayesian clinical trial design | |
| 650 | 4 | |a Bayesian type I error rate | |
| 650 | 4 | |a biosimilars | |
| 650 | 4 | |a equivalence trial | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 700 | 1 | |a Hu, Kuolung |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Joseph G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biometrics |d 1946 |g 76(2020), 2 vom: 21. Juni, Seite 630-642 |w (DE-627)NLM00179423X |x 1541-0420 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2020 |g number:2 |g day:21 |g month:06 |g pages:630-642 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/biom.13163 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2020 |e 2 |b 21 |c 06 |h 630-642 | ||